ArticleTranslational cancer research2020
Bostrycin inhibits growth of tongue squamous cell carcinoma cells by inducing mitochondrial apoptosis.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Lignocellulosic substrates as starting materials for the production of bioactive biopigments.Food chemistry: X · 2022Article
- Recent Advances inJournal of fungi (Basel, Switzerland) · 2022Review
- Non-coding RNA-related antitumor mechanisms of marine-derived agents.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBostrycin is a natural pigment product with anthraquinone skeleton, which has excellent inhibitory effect on a variety cancer cells. However, its suppression on tongue squamous cell carcinoma has not been reported.
methodsWe studied the effects of bostrycin on the cell growth and apoptosis of tongue squamous cell carcinoma
resultsBostrycin could inhibit the proliferation and migration of tongue squamous cell carcinoma by arresting cell cycle at G2/M phase, and inducing cell apoptosis with mitochondrial membrane potential changes. West-blotting analysis also showed that bostrycin could inhibit the growth of tongue squamous cell carcinoma cells by activating the apoptosis-related signal proteins especially in mitochondrial apoptotic pathway.
conclusionsBostrycin can be used as a new anti-tumor candidate drug for further research. Our study provides reference for the potential application of bostrycin in the treatment of the tongue squamous cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.